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The data presented in this article are related to the research article
entitled “A critical role of transcription factor YY1 in rheumatoid
arthritis by regulation of interleukin-6” (J. Lin, Y. He, J. Chen, Z. Zeng,
B. Yang, Q. Ou, 2016) [1]. The article describes YY1 overexpression is
speciﬁc for RA, but not for SLE, SS, DM or MCTD. In early RA, YY1
expression is also increased. In asymptomatic subjects with RF or
ACPA positive who have high risk for developing RA, the YY1
expression is not increased obviously. Moreover, YY1 expression is
positively correlated with serum CRP or ESR. In RA patients treated
with anti-IL-6R monoclonal Ab tocilizumab, there is no signiﬁcant
difference in YY1 expression after IL-6 blocking therapy.
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Biology
ore speciﬁc sub-
ject areaArthritis and Rheumatologyvier Inc. This is an open access article under the CC BY license
/j.jaut.2016.10.008
, 350005, Fujian, China.
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acquiredReal-time Polymerase Chain Reaction (Applied Biosystems PCR System
7500); Correlation analysisata format Analyzed
xperimental
factorsPeripheral blood mononuclear cells (PBMC) from RA, SLE, SS, DM or MCTD
patients were freshly isolated. PBMC from early RA and established RA
patients; PBMC from RA patients treated with tocilizumab were also col-
lected. RNA was extracted from PBMC.xperimental
featuresYY1 expression in autoimmune diseases or in RA patients treated with
tocilizumab was detected by real-time PCR.ata source
locationThe First Afﬁliated Hospital of Fujian Medical University, Fuzhou, Chinaata accessibility Data are presented in this articleD
Value of the data
 These data can be compared to other scientiﬁc data addressing the role of YY1 in other disease.
 These data provide insight into the function of YY1 in IL-6 production which can be of value for
research groups from related ﬁelds.
 These data allow other researchers to extend the role of YY1 in RA study.1. Data
Data describes YY1 expression in RA, SLE, SS, DM and MCTD patients. The data show YY1 is
overexpressed in RA, but not in SLE, SS, DM or MCTD patients (Fig. 1). YY1 expression is also increased
in early RA compared to healthy control (Fig. 2A), however, YY1 expression in asymptomatic subjects
with RF or ACPA positive is not increased signiﬁcantly (Fig. 2B). Furthermore, YY1 expression is
positively correlated with serum CRP or ESR in RA (Fig. 3). However, in RA patients treated with anti-
IL-6R monoclonal Ab tocilizumab, the YY1 expression after IL-6 blocking therapy is not increased
signiﬁcantly (Fig. 4).MC from RA, SLE, SS, DM and MCTD patients. YY1 expression was over-expressed in RA compared
patients. HD: healthy donors; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; SS:
rmatomyositis; MCTD: mixed connective tissue disease. nPo0.05.
Fig. 2. Increased expression of YY1 in early RA, but not in asymptomatic subjects with RF or ACPA positive. A, YY1 expression in
early RA and established RA. B, YY1 expression in asymptomatic subjects with RF or ACPA positive. HD: healthy donors. RF:
rheumatoid factor; ACPA: anti-citrullinated protein antibodies. nPo0.05.
Fig. 3. Positive correlation between YY1 expression and CRP or ESR. A, Correlation analysis of YY1 expression and CRP. B,
Correlation analysis of YY1 expression and ESR. CRP: C-reaction protein; ESR: erythrocyte sedimentation rate.
J. Lin et al. / Data in Brief 9 (2016) 1034–103810362. Experimental design, materials and methods
2.1. Patients
20 patients with systemic lupus erythematosus (SLE) fulﬁlled the 1997 revised American College of
Rheumatology criteria [2], 10 patients with Sjogren's syndrome (SS) fulﬁlled the American–European
Group Criteria [3], 10 patients with dermatomyositis (DM) fulﬁlled criteria described by Medsger [4],
Fig. 4. YY1 expression in RA patients treated with tocilizumab. PBMC from RA patients 14, 28, 42 and 56 days’ post tocilizumab
treated was collected for detection of YY1 expression.
J. Lin et al. / Data in Brief 9 (2016) 1034–1038 10378 patients with mixed connective tissue disease (MCTD) fulﬁlled the classiﬁcation criteria described
by Alarcon-Segovia [5] were enrolled for the study. Peripheral blood mononuclear cells (PBMC) from
the patients was isolated by Ficoll. PBMC from early RA patients and asymptomatic subjects with RF
or ACPA positive, PBMC from 6 RA patients before and after treated with tocilizumab (TCZ) for two
months were also collected. All the PBMC collected was for detection of YY1 expression. Study pro-
tocols were approved by the Institutional Medical Ethics Review Board of the First Afﬁliated Hospital
of Fujian Medical University, Fuzhou, China.2.2. Real-time PCR analysis
Total RNA was extracted from PBMC cells, and real-time PCR was performed as previously
described by us [6,7]. The primers used in this study was as described by us [1].2.3. Statistical analysis
Differences between groups was analyzed by unpaired Student's t-test. Correlation analyses was
done by Microsoft Excel. For all statistical analyses, P values less than 0.05 was considered statistically
signiﬁcant. All statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, San
Diego, CA).Acknowledgements
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